[{"orgOrder":0,"company":"Jonsson Comprehensive Cancer Center","sponsor":"National Cancer Institute | Oncoceutics Inc | University of California, Los Angeles","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"Dopamine D2 receptor (D2R)||DRD2","graph1":"Oncology","graph2":"Phase I","graph3":"Jonsson Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jonsson Comprehensive Cancer Center \/ National Cancer Institute | Oncoceutics Inc | University of California, Los Angeles","highestDevelopmentStatusID":"6","companyTruncated":"Jonsson Comprehensive Cancer Center \/ National Cancer Institute | Oncoceutics Inc | University of California, Los Angeles"},{"orgOrder":0,"company":"University of Nebraska","sponsor":"Chimerix","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"Dopamine D2 receptor (D2R)||DRD2","graph1":"Oncology","graph2":"Phase II","graph3":"University of Nebraska","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Nebraska \/ Chimerix","highestDevelopmentStatusID":"8","companyTruncated":"University of Nebraska \/ Chimerix"},{"orgOrder":0,"company":"Rutgers, The State University of New Jersey","sponsor":"National Cancer Institute | Rutgers Cancer Institute of New Jersey | Oncoceutics Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"Dopamine D2 receptor (D2R)||DRD2","graph1":"Oncology","graph2":"Phase I","graph3":"Rutgers, The State University of New Jersey","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rutgers, The State University of New Jersey \/ National Cancer Institute | Rutgers Cancer Institute of New Jersey | Oncoceutics Inc","highestDevelopmentStatusID":"6","companyTruncated":"Rutgers, The State University of New Jersey \/ National Cancer Institute | Rutgers Cancer Institute of New Jersey | Oncoceutics Inc"},{"orgOrder":0,"company":"Fox Chase Cancer Center","sponsor":"Oncoceutics Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"Dopamine D2 receptor (D2R)||DRD2","graph1":"Oncology","graph2":"Phase II","graph3":"Fox Chase Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fox Chase Cancer Center \/ Oncoceutics Inc","highestDevelopmentStatusID":"8","companyTruncated":"Fox Chase Cancer Center \/ Oncoceutics Inc"},{"orgOrder":0,"company":"Brown University","sponsor":"Rhode Island Hospital | Bristol Myers Squibb | Oncoceutics Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"Dopamine D2 receptor (D2R)||DRD2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Brown University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brown University \/ Rhode Island Hospital | Bristol Myers Squibb | Oncoceutics Inc","highestDevelopmentStatusID":"7","companyTruncated":"Brown University \/ Rhode Island Hospital | Bristol Myers Squibb | Oncoceutics Inc"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Oncoceutics Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"Dopamine D2 receptor (D2R)||DRD2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Oncoceutics Inc","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Oncoceutics Inc"},{"orgOrder":0,"company":"Chimerix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"Dopamine D2 receptor (D2R)||DRD2","graph1":"Oncology","graph2":"Phase II","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chimerix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chimerix \/ Undisclosed"},{"orgOrder":0,"company":"Chimerix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"Dopamine D2 receptor (D2R)||DRD2","graph1":"Oncology","graph2":"Phase III","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chimerix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chimerix \/ Undisclosed"},{"orgOrder":0,"company":"Chimerix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"Dopamine D2 receptor (D2R)||DRD2","graph1":"Oncology","graph2":"Phase III","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chimerix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chimerix \/ Undisclosed"},{"orgOrder":0,"company":"Chimerix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"Dopamine D2 receptor (D2R)||DRD2","graph1":"Oncology","graph2":"Phase III","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chimerix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chimerix \/ Undisclosed"},{"orgOrder":0,"company":"Chimerix","sponsor":"Oncoceutics Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"Dopamine D2 receptor (D2R)||DRD2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chimerix \/ Oncoceutics Inc","highestDevelopmentStatusID":"7","companyTruncated":"Chimerix \/ Oncoceutics Inc"},{"orgOrder":0,"company":"Chimerix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"DRD2","graph1":"Oncology","graph2":"Phase III","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chimerix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chimerix \/ Undisclosed"},{"orgOrder":0,"company":"Chimerix","sponsor":"Oncoceutics Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"DRD2","graph1":"Oncology","graph2":"Phase III","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chimerix \/ Oncoceutics Inc","highestDevelopmentStatusID":"10","companyTruncated":"Chimerix \/ Oncoceutics Inc"},{"orgOrder":0,"company":"Chimerix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"DRD2","graph1":"Oncology","graph2":"Phase III","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chimerix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chimerix \/ Undisclosed"},{"orgOrder":0,"company":"Chimerix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"DRD2","graph1":"Oncology","graph2":"Phase III","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chimerix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chimerix \/ Undisclosed"},{"orgOrder":0,"company":"Oncoceutics Inc","sponsor":"Chimerix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Dordaviprone","moa":"DRD2","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoceutics Inc","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Capsule","sponsorNew":"Oncoceutics Inc \/ Chimerix","highestDevelopmentStatusID":"8","companyTruncated":"Oncoceutics Inc \/ Chimerix"},{"orgOrder":0,"company":"Oncoceutics Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"DRD2","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoceutics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oncoceutics Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oncoceutics Inc \/ Undisclosed"},{"orgOrder":0,"company":"Chimerix","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Dordaviprone","moa":"DRD2","graph1":"Oncology","graph2":"Phase III","graph3":"Chimerix","amount2":0.93999999999999995,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.93999999999999995,"dosageForm":"Capsule","sponsorNew":"Chimerix \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Chimerix \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Chimerix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"DRD2","graph1":"Oncology","graph2":"Phase III","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chimerix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chimerix \/ Undisclosed"},{"orgOrder":0,"company":"Chimerix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"DRD2","graph1":"Oncology","graph2":"Phase III","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chimerix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chimerix \/ Undisclosed"},{"orgOrder":0,"company":"Chimerix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"DRD2","graph1":"Oncology","graph2":"Phase III","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chimerix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chimerix \/ Undisclosed"},{"orgOrder":0,"company":"Chimerix","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Dordaviprone","moa":"DRD2","graph1":"Oncology","graph2":"Phase III","graph3":"Chimerix","amount2":0.93999999999999995,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.93999999999999995,"dosageForm":"Capsule","sponsorNew":"Chimerix \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Chimerix \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Oncoceutics Inc","sponsor":"Chimerix","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"DRD2","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoceutics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oncoceutics Inc \/ Chimerix","highestDevelopmentStatusID":"8","companyTruncated":"Oncoceutics Inc \/ Chimerix"},{"orgOrder":0,"company":"Oncoceutics Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"DRD2","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoceutics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oncoceutics Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oncoceutics Inc \/ Undisclosed"},{"orgOrder":0,"company":"Oncoceutics Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"DRD2","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoceutics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oncoceutics Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oncoceutics Inc \/ Undisclosed"},{"orgOrder":0,"company":"Chimerix","sponsor":"Oncoceutics Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"DRD2","graph1":"Oncology","graph2":"Phase II","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chimerix \/ Oncoceutics Inc","highestDevelopmentStatusID":"8","companyTruncated":"Chimerix \/ Oncoceutics Inc"},{"orgOrder":0,"company":"Chimerix","sponsor":"Oncoceutics Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"DRD2","graph1":"Oncology","graph2":"Phase II","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chimerix \/ Oncoceutics Inc","highestDevelopmentStatusID":"8","companyTruncated":"Chimerix \/ Oncoceutics Inc"},{"orgOrder":0,"company":"Pacific Pediatric Neuro-Oncology Consortium","sponsor":"Kazia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Dordaviprone","moa":"||DRD2","graph1":"Oncology","graph2":"Undisclosed","graph3":"Pacific Pediatric Neuro-Oncology Consortium","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pacific Pediatric Neuro-Oncology Consortium \/ Kazia Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Pacific Pediatric Neuro-Oncology Consortium \/ Kazia Therapeutics"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Pacific Pediatric Neuro-Oncology Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"||DRD2","graph1":"Oncology","graph2":"Phase II","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kazia Therapeutics \/ Pacific Pediatric Neuro-Oncology Consortium","highestDevelopmentStatusID":"8","companyTruncated":"Kazia Therapeutics \/ Pacific Pediatric Neuro-Oncology Consortium"},{"orgOrder":0,"company":"Chimerix","sponsor":"Gustave Roussy","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"Dopamine D2 receptor (D2R)||DRD2","graph1":"Oncology","graph2":"Phase III","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chimerix \/ Gustave Roussy","highestDevelopmentStatusID":"10","companyTruncated":"Chimerix \/ Gustave Roussy"}]
Find Clinical Drug Pipeline Developments & Deals for Dordaviprone
Details :
Through the acquisition, Jazz will strengthen it's oncology pipeline, which includes ONC201 (dordaviprone). It is being evaluated in the late-stage for the treatment of H3 K27M-mutant diffuse glioma.
Details :
Through the acquisition, Jazz will strengthen it's oncology pipeline, which includes ONC201 (dordaviprone). It is being in the evaluated late-stage for the treatment of H3 K27M-mutant diffuse glioma.
Details :
ONC201 (dordaviprone) is a novel first-in-class small molecule imipridone that selectively targets the mitochondrial protease ClpP and dopamine receptor D2 for recurrent H3 K27M-Mutant diffuse glioma.
Details :
ONC201 (dordaviprone) is a novel first-in-class small molecule imipridone that selectively targets the mitochondrial protease ClpP and dopamine receptor D2 for recurrent H3 K27M-Mutant diffuse glioma.
Details :
ONC201 (dordaviprone) targets the targets the mitochondrial protease ClpP and dopamine receptor D2. It is being evaluated for the treatment of recurrent H3 K27M-mutant diffuse glioma.
Details :
ONC201 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Meningioma.
Details :
ONC201 is a new drug candidate that kills cancer cells but not normal cells in laboratory studies and has been previously evaluated in a phase I clinical trial in advanced cancer patients.
Details :
Dordaviprone is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Glioma.
Details :
ONC201 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diffuse Intrinsic Pontine Glioma.
Reset All
